Rachel A. Rigg

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

Cassandra P. Loren, Joseph E. Aslan, Rachel A. Rigg et al. · Thrombosis Research · 2014 · 76 citations · Full text

Thrombopoiesis, Thrombosis, Aggregate Formation +11

Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function

Rachel A. Rigg, Joseph E. Aslan, Laura D. Healy et al. · American Journal of Physiology-Cell Physiology · 2015 · 74 citations · Full text

Tyrosine Kinase, Immunology, Blood Cell +25

Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection

Linda Labberton, Ellinor Kenne, Andy T. Long et al. · Nature Communications · 2016 · 74 citations · Full text

A physical sciences network characterization of circulating tumor cell aggregate transport

Michael R. King, Kevin G. Phillips, Annachiara Mitrugno et al. · American Journal of Physiology-Cell Physiology · 2015 · 65 citations · Full text

Engineering, Biological Microenvironments, Cell Biophysics +21

Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions

Rachel A. Rigg, Laura D. Healy, Tiffany T. Chu et al. · Platelets · 2018 · 41 citations · Full text

Immunology, Serine Proteases, Granule Release +19